| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.97M | - | |
| CEO | 143.1K | $1.51M | - | |
| Other | 52.0K | $549.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 16, 2017 | Gallagher Carol Giltner | Director | Sale+OE | 1,184 | $15.25 | $18,056.00 | -1.1% | |
| May 16, 2017 | McGrath John | EVP &Chief Financial Officer | Sale+OE | 4,000 | $15.11 | $60,440.00 | -1.7% | |
| May 16, 2017 | Clark Mitchall G. | EVP &Chief R &Qa Officer | Sale+OE | 3,873 | $15.25 | $59,063.25 | -2.5% | |
| May 16, 2017 | Soffer Gad | EVP &Chief Strategy Officer | Sale+OE | 12,674 | $15.16 | $192,098.06 | -2.4% | |
| May 15, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sale+OE | 7,604 | $14.99 | $113,983.96 | -2.0% | |
| Apr 26, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,200 | $17.56 | $126,405.00 | -0.5% | |
| Apr 17, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 6,000 | $17.28 | $103,680.00 | -1.6% | |
| Apr 11, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,200 | $17.03 | $122,598.00 | -0.7% | |
| Mar 28, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 16,000 | $20.06 | $320,943.66 | -1.1% | |
| Mar 23, 2017 | McGrath John | EVP &Chief Financial Officer | Sell | 14,000 | $20.65 | $289,045.00 | -5.7% |